Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Eli Lilly and Sangamo Therapeutics have entered into a licensing agreement worth over $1.4bn to deliver genomic medicines for ...

Sangamo, which has been having cash problems, will receive $18 million upfront in licensing fees for its AAV capsid that in ...

Lilly is the third company to partner with Sangamo on STAC-BBB after Astellas Gene Therapies, which paid $20 million upfront ...

Sangamo Therapeutics Inc., a genomic medicine company, has entered into a license agreement with Eli Lilly and Company.

Sangamo Therapeutics, Inc.'s $18M Eli Lilly deal boosts CNS genomic medicines. Fabry gene therapy data in 2025 is key for ...

Sangamo Therapeutics (SGMO) announced it has entered into a license agreement with Eli Lilly (LLY), allowing Lilly to leverage Sangamo’s novel ...

Eli Lilly licenses Sangamo's BBB-penetrating AAV capsid for CNS disease with $18M upfront; deal includes option for 4 more ...

Agreement grants Lilly rights to employ Sangamo’s novel proprietary capsid, STAC-BBB, for up to five potential disease targets Sangamo to receive an $18 million upfront license fee and is ...

Sangamo Therapeutics shares are surging in Thursday's after-hours session after the company announced a new agreement with ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced it has entered into a license agreement with Eli Lilly and Company (“Lilly”), allowing ...